Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
February 05, 2019 12:02 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., and WALTHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals ernennt Thomas Lackner zum Senior Vice President, Head of Europe
January 31, 2019 20:03 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Kentucky, WALTHAM, Massachusetts, und ZUG, Schweiz, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), ein biopharmazeutisches Unternehmen im Bereich der...
Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe
January 31, 2019 09:00 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., WALTHAM, Mass. and ZUG, Switzerland, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the...
Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 07:00 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., and WALTHAM Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy
December 20, 2018 16:01 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy
December 20, 2018 07:00 ET
|
Apellis Pharmaceuticals, Inc.
Phase 3 geographic atrophy program enrollment timeline currently unchanged; program enrollment is expected to restart in Q2 2019 and enrollment completion is expected in Q1 2020 CRESTWOOD, Ky. and...
Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
December 03, 2018 13:01 ET
|
Apellis Pharmaceuticals, Inc.
- New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) - CAD patients treated with APL-2 had...
Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
December 02, 2018 12:01 ET
|
Apellis Pharmaceuticals, Inc.
Treatment with APL-2 in eculizumab-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) resulted in broad control of hemolysis and normalization of mean hemoglobin to 12.2 g/dL by day 85, an...
Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer
November 20, 2018 07:00 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results
November 13, 2018 08:00 ET
|
Apellis Pharmaceuticals, Inc.
- Commenced Phase 3 Program of APL-2 in Geographic Atrophy (GA) - - Cash Position of $220.6 Million at Quarter-End - CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis...